A Systematic Review of Economic Studies on Biological Agents Used to Treat Crohn’s Disease

Effect of Adalimumab on Work Productivity and Indirect Costs in Moderate to Severe Crohn’s Disease: A Meta-Analysis

(2016) David G Binion et al.   CANADIAN JOURNAL OF GASTROENTEROLOGY

Health Care Resource Use and Costs for Crohn’s Disease before and after Infliximab Therapy

(2016) Dustin E Loomes et al.   CANADIAN JOURNAL OF GASTROENTEROLOGY

A systematic review and economic evaluation of the use of tumour necrosis factor-alpha (TNF-α) inhibitors, adalimumab and infliximab, for Crohn’s disease

(2014) J Dretzke et al.   HEALTH TECHNOLOGY ASSESSMENT

Adalimumab improves patient-reported outcomes and reduces indirect costs in patients with moderate to severe Crohn's disease: Results from the CARE trial

(2012) Edouard Louis et al.   Journal of Crohns & Colitis

Cost-Utility Analysis of Biologic Treatments for Moderate-to-Severe Crohn's Disease

(2012) Derek H. Tang et al.   PHARMACOTHERAPY

Strategies for the Prevention of Postoperative Recurrence in Crohn's Disease: Results of a Decision Analysis

(2011) Ashwin N Ananthakrishnan et al.   AMERICAN JOURNAL OF GASTROENTEROLOGY

Assessing Response and Loss of Response to Biological Therapies in IBD

(2011) Henit Yanai et al.   AMERICAN JOURNAL OF GASTROENTEROLOGY

Efficacy of Biological Therapies in Inflammatory Bowel Disease: Systematic Review and Meta-Analysis

(2011) Alexander C Ford et al.   AMERICAN JOURNAL OF GASTROENTEROLOGY

Certolizumab Pegol Compared to Natalizumab in Patients with Moderate to Severe Crohn’s Disease: Results of a Decision Analysis

(2011) Ashwin N. Ananthakrishnan et al.   DIGESTIVE DISEASES AND SCIENCES

Optimal use and cost-effectiveness of biologic therapies in inflammatory bowel disease

(2011) Antonio Di Sabatino et al.   Internal and Emergency Medicine

Long-term Durability of Infliximab Treatment in Crohnʼs Disease and Efficacy of Dose “Escalation” in Patients Losing Response

(2011) María Chaparro et al.   JOURNAL OF CLINICAL GASTROENTEROLOGY

Managing the long term care of inflammatory bowel disease patients: The cost to European health care providers

(2011) James Buchanan et al.   Journal of Crohns & Colitis

Adalimumab real-world dosage pattern and predictors of weekly dosing: Patients with Crohn's disease in the United States

(2011) Edward V. Loftus et al.   Journal of Crohns & Colitis

Canadian cost-utility analysis of initiation and maintenance treatment with anti-TNF-α drugs for refractory Crohn's disease

(2011) Gord Blackhouse et al.   Journal of Crohns & Colitis

Cost Effectiveness of Treatments for Inflammatory Bowel Disease

(2011) Keith Bodger   PHARMACOECONOMICS

Health-economic analysis: cost-effectiveness of scheduled maintenance treatment with infliximab for Crohn’s disease - modelling outcomes in active luminal and fistulizing disease in adults

(2010) J. LINDSAY et al.   ALIMENTARY PHARMACOLOGY & THERAPEUTICS

Costs of care for Crohn’s disease following the introduction of infliximab: a single-centre UK experience

(2010) M. B. Sprakes et al.   ALIMENTARY PHARMACOLOGY & THERAPEUTICS

Adherence to adalimumab therapy in Crohnʼs disease: A French multicenter experience

(2010) Vincent Billioud et al.   INFLAMMATORY BOWEL DISEASES

Inflammatory bowel disease-attributable costs and cost-effective strategies in the United States

(2010) K. T. Park et al.   INFLAMMATORY BOWEL DISEASES

Dosage adjustment during long-term adalimumab treatment for Crohnʼs disease: Clinical efficacy and pharmacoeconomics

(2010) William J. Sandborn et al.   INFLAMMATORY BOWEL DISEASES

Healthcare Rationing by Proxy

(2010) John F.P. Bridges et al.   PHARMACOECONOMICS

Adherence to infliximab maintenance therapy and health care utilization and costs by Crohn’s disease patients

(2009) Sunanda V. Kane et al.   ADVANCES IN THERAPY

Cost-effectiveness of biological therapy for Crohn’s disease: Markov cohort analyses incorporating United Kingdom patient-level cost data

(2009) K. BODGER et al.   ALIMENTARY PHARMACOLOGY & THERAPEUTICS

Management of Crohn's Disease in Adults

(2009) Gary R Lichtenstein et al.   AMERICAN JOURNAL OF GASTROENTEROLOGY

Cost-effectiveness of adalimumab for the maintenance of remission in patients with Crohnʼs disease

(2009) Edward V. Loftus et al.   EUROPEAN JOURNAL OF GASTROENTEROLOGY & HEPATOLOGY

Resource use and societal costs for Crohnʼs disease in Sweden

(2009) Johan Mesterton et al.   INFLAMMATORY BOWEL DISEASES

World Gastroenterology Organization Practice Guidelines for the Diagnosis and Management of IBD in 2010

(2009) Charles N. Bernstein et al.   INFLAMMATORY BOWEL DISEASES

Efficacy Does Not Necessarily Translate to Cost Effectiveness: A Case Study in the Challenges Associated With 21st-Century Cancer Drug Pricing

(2009) Bruce E. Hillner et al.   JOURNAL OF CLINICAL ONCOLOGY

Cost Utility of Adalimumab versus Infliximab Maintenance Therapies in the United States for Moderately to Severely Active Crohnʼs Disease

(2009) Andrew P. Yu et al.   PHARMACOECONOMICS

Cost-Effectiveness of Scheduled Maintenance Treatment with Infliximab for Pediatric Crohn's Disease

(2009) Yogesh Suresh Punekar et al.   VALUE IN HEALTH

The cost effectiveness and budget impact of natalizumab for formulary inclusion

(2009) Justin Bakhshai et al.   JOURNAL OF MEDICAL ECONOMICS

Effects of Adalimumab Therapy on Incidence of Hospitalization and Surgery in Crohn's Disease: Results From the CHARM Study

(2008) Brian G. Feagan et al.   GASTROENTEROLOGY

Direct Health Care Costs of Crohn's Disease and Ulcerative Colitis in US Children and Adults

(2008) Michael D. Kappelman et al.   GASTROENTEROLOGY

Loss of Treatment Response to Infliximab Maintenance Therapy in Crohn's Disease: A Payor Perspective

(2008) Eric Qiong Wu et al.   VALUE IN HEALTH

Assessing cost-effectiveness in healthcare: history of the $50,000 per QALY threshold

(2008) Scott D Grosse   Expert Review of Pharmacoeconomics & Outcomes Research